What the FDA labels say about taking them together
Anakinra and certolizumab
Certolizumab's FDA label of February 24, 2026 names anakinra in its drug interactions section; the anakinra label PlainMeds reads does not name certolizumab. The certolizumab label: “An increased risk of serious infections has been seen in clinical studies of other TNF-blocking agents used in combination with anakinra or abatacept, with no added benefit.”
Check it at the source: the anakinra FDA label on DailyMed (effective April 3, 2026, Swedish Orphan Biovitrum AB (publ)); the certolizumab FDA label on DailyMed (effective February 24, 2026, UCB, Inc.).
What does the anakinra label say about certolizumab?
Anakinra's label (effective April 3, 2026) does not name certolizumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Kineret), Swedish Orphan Biovitrum AB (publ), effective April 3, 2026 (SPL set d9d74915-6606-4570-9c52-c4001d3177de), via openFDA; the full label on DailyMed
What does the certolizumab label say about anakinra?
Certolizumab label, drug interactionsAn increased risk of serious infections has been seen in clinical studies of other TNF-blocking agents used in combination with anakinra or abatacept, with no added benefit.
Certolizumab label, warnings and precautionsAdvise patients to seek immediate medical attention if symptoms develop; consider discontinuing CIMZIA in patients with confirmed abnormalities. ( 5.7 ) Use with Anakinra, Abatacept, Rituximab and Natalizumab:
Source: FDA drug label (Cimzia), BLA125160 (Ucb Inc), as published by UCB, Inc., effective February 24, 2026 (SPL set b4c2c9dc-a0bb-4d64-a667-a67ebe88392d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Anakinra | Certolizumab | |
|---|---|---|
| Labeled for | n/a | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $6,094.02 per syringe 2x200 mg/mL syringe kit |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once